With AstraZeneca, we are evaluating the safety and efficacy of tenapanor in three ongoing Phase 2 clinical trials for three different indications. Our lead indication is the treatment of hyperphosphatemia in ESRD patients. We and AstraZeneca are also evaluating the potential for tenapanor’s long-term benefit in the treatment of patients with CKD. Trials are underway to understand the potential impact tenapanor may have on markers of kidney disease and fluid status in CKD patients. We and AstraZeneca are also working to determine the best approach for the development of tenapanor in IBS-C and the renal indications that we are evaluating. Through our collaboration partner, Sanofi, we are also continuing discovery efforts with our NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD patients. We also have three internal on-going discovery efforts aimed at non-systemic agents to treat IBD and hyperkalemia and to modulate chloride transport.